Advertisement

Clinical Rheumatology

, Volume 36, Issue 5, pp 1197–1199 | Cite as

Is secukinumab a safe alternative treatment for ankylosing spondylitis with Guillain Barré syndrome after anti-TNF-α treatment? Case report and literature review

  • Savvas PsarelisEmail author
  • Andreas P. D. Hajineocli
  • Eleni Hadjicosta
  • Hugh St. A. Elliott
  • Paul Johnson
Case Based Review

Abstract

In this report, we aim to add to the existing body of evidence regarding a link between anti- tumor necrosis factor alpha (anti-TNF-α) treatment and demyelination leading to neurological disorders, specifically Guillain Barré syndrome (GBS), and treatment with an interleukin-17A (IL17A) antagonist as a safe alternative for ankylosing spondylitis (AS). A literature review was carried out of current research concerning anti-TNF-α and induced GBS. Only papers published in English were reviewed and only peer-reviewed journals searched. Papers published up to September 2016 were included. Animal studies were excluded. Data bases searched for publications online included: Pub Med, Google Scholar, The Cochrane Library, and Web of Science. Searched terms include “anti-TNF” and “Guillain Barré”, “IL17 Ankylosing Spondylitis”, “Secukinumab” and “TNF-α”, “adalimumab”, “infliximab”, and “etanercept”. All combinations and outcomes were used, and from these searches, a provisional reference list was constructed. The short-listed articles were read and their reference lists were reviewed. The electromyogram done for the patient showed demyelination, the MRI of the brain showed no pathologies, and the MRI of the spine was consistent with ankylosing spondylitis without myelopathy. The lumbar puncture results showed albuminocytological dissociation that was consistent with GBS. TNF has a proinflammatory action, and various immunoregulatory actions that, together, seem to promote the development of peripheral neuropathies syndromes in the organism. However, there is no clear mechanism of why or how anti-TNF-α treatment can induce a demyelinating event in a patient. In the case presented, it was found that the patient developed GBS due to treatment with etanercept, an anti-TNF agent. The treatment was stopped immediately. Two years later, he was switched to secukinumab and has been well controlled for the last 8 months with no neurological findings.

Keywords

Ankylosing Spondylitis (Rheumatic Disease) Anti-TNF-α Guillain Barré syndrome Secukinumab 

Notes

Compliance with ethical standards

Disclosures

None.

References

  1. 1.
    Fong Y et al (1989) Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 5 appearance during lethal bacteremia. J Exp Med 170:1627CrossRefPubMedGoogle Scholar
  2. 2.
    Monaco C et al (2014) Anti-TNF therapy: past, present and future. Int Immunol 27(1):55–62CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Dörner T, Strand V, Castañeda G et al (2012) The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis. doi: 10.1136/annrheumdis-2012-202715 PubMedCentralGoogle Scholar
  4. 4.
  5. 5.
    Xu W, Ma C, Wu J, Zhu J (2013) Journal of. Neurosci Res 91(Issue 7):871–881Google Scholar
  6. 6.
    Osman T, Yavuz KA et al (2012) Guillain-Barre syndrome developing during infliximab treatment for psoriatic arthritis: a case report. J Clin Anal Med 7(1)Google Scholar
  7. 7.
    Aznar J, Porta-Etessam J, Ossorio J, Rosales-Alexander J (2013) Tumor necrosis factor-alpha antagonist and demielynating diseases. J Neurol Neurosci 4(3:2)Google Scholar
  8. 8.
    Bradshaw MJ, Mobley BC et al (2016) Autopsy-proven demyelination associated with infliximab treatment. Neurol Neuroimmunol, Neuroinflamm 3:e205. doi: 10.1212/NXI.0000000000000205 CrossRefGoogle Scholar
  9. 9.
    Kaltsonoudis E, Voulgari PV, Konitsiotis S, Drosos AA (2014) Demyelination and other neurological adverse events after anti-TNF therapy. Autoimmun Rev 13:54–58CrossRefPubMedGoogle Scholar
  10. 10.
    Shin I, Baer A, Kwon H, Papadopoulos E, Siegel J (2006) Guillain-Barré and miller fisher syndromes occurring with tumor necrosis factor α antagonist therapy. Arthritis & Rheumatism. 54(5):1429–1434CrossRefGoogle Scholar
  11. 11.
    Lozeron P, Denier C, Lacroix C, Adams D. (2009) Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-α–blocker therapy. Arch Neurol 66(4)Google Scholar
  12. 12.
    Seror R, Richez C, Sordet C, Rist S, Gossec L, Direz G et al (2013) Pattern of demyelination occurring during anti-TNF- therapy: a French national survey. Rheumatology 52(5):868–874CrossRefPubMedGoogle Scholar
  13. 13.
    Mohan N, Edwards E, Cupps T, Oliverio P, Sandberg G, Crayton H et al (2001) Demyelination occurring during anti-tumor necrosis factor therapy for inflammatory arthritides. Arthritis & Rheumatism 44(12):2862–2869CrossRefGoogle Scholar
  14. 14.
    Tsouni P, Bill O, Truffert A, Liaudat C, Ochsner F, Steck A et al (2015) Anti-TNF alpha medications and neuropathy. J Peripher Nerv Syst 20(4):397–402CrossRefPubMedGoogle Scholar
  15. 15.
    Appel H, Maier R, Wu P et al (2011) Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther 13:R95CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Raychaudhuri SK, Saxena A, Raychaudhuri SP (2015) Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis. Clin Rheumatol 34:1019–1023. doi: 10.1007/s10067-015-2961-7 CrossRefPubMedGoogle Scholar
  17. 17.
    Noordenbos T, Yeremenko N, Gofita I et al (2012) Interleukin-17–positive mast cells contribute to synovial inflammation in Spondylarthritis. ARTHRITIS & RHEUMATISM 64(1):99–109. doi: 10.1002/art.33396 CrossRefGoogle Scholar
  18. 18.
    Raychaudhuri SP, Raychaudhuri SK (2016) IL-23/IL-17 axis in spondyloarthritis-bench to bedside. Clin Rheumatol 35:1437–1441CrossRefPubMedGoogle Scholar
  19. 19.
    Dominique Baeten MD, Joachim Sieper MD, Jürgen Braun MD et al (2015) Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med 373:2534–2548. doi: 10.1056/NEJMoa1505066 CrossRefPubMedGoogle Scholar
  20. 20.
    Sieper J, Deodhar A, Marzo-Ortega H et al (2016) Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. Ann Rheum Dis. doi: 10.1136/annrheumdis-2016-210023 Google Scholar
  21. 21.
    Ling L et al (2016) Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res 9:39–50Google Scholar
  22. 22.
    Sarah LG et al (2014) The IL-23- IL-17 immune axis: from mechanism to therapeutic testing. Nat Rev Immunol 14:585–600CrossRefGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2017

Authors and Affiliations

  • Savvas Psarelis
    • 1
    • 2
    Email author
  • Andreas P. D. Hajineocli
    • 1
  • Eleni Hadjicosta
    • 1
  • Hugh St. A. Elliott
    • 1
  • Paul Johnson
    • 1
  1. 1.St George’s, University of London Medical Programme, Delivered in Cyprus by the University of Nicosia Medical SchoolNicosiaCyprus
  2. 2.Rheumatology DepartmentNicosia General HospitalStrovolosCyprus

Personalised recommendations